

1 **Supplementary Informations**

2 **Methods**

3 **Study subjects**

4 We enrolled 42 patients positive for SARS-CoV-2 who were admitted to the
5 Jikei University Hospital between March and May 2020 (approved by the Institutional
6 Review Board at The Jikei University School of Medicine (Number: 32-055(10130)).
7 COVID-19 patients were recruited on the basis of positive PCR tests for SARS-CoV-2
8 RNA obtained by nasopharyngeal swabs. The eventual degree of COVID-19 severity was
9 categorized as mild or severe on the basis of WHO 2020 scoring (**Table S2**). 11 Patients
10 with severe COVID-19 at admission were excluded. At the time of admission, all
11 COVID-19 patients were scored as having a mild status (WHO score = 3). Based on the
12 clinical disease course after admission, we divided 31 patients in two groups (namely,
13 Group 1: mild cases (WHO score \leq 4), and Group 2: severe cases (WHO score \geq 5)). All
14 patients received standard therapy without corticosteroids according to Clinical
15 management of COVID-19 interim guidance by WHO. 10 healthy age-matched donors
16 were recruited at Omiya City Clinic, Saitama for routine medical examination between
17 March and April 2019 (approved by the Institutional Review Board at The Institute of
18 Medical Science, The University of Tokyo (Number: 28-19-0907). The medical records
19 of COVID-19 patients and healthy donors were analyzed retrospectively. 31 serum
20 samples taken at admission from COVID-19 patients and 10 serum samples taken from
21 healthy donors were separated by centrifugation at 3000 rpm for 10 min at 4°C. The
22 supernatant was collected into a new tube and the serum sample was stored at -80°C until
23 use.
24

25 **Isolation of EVs**

26 Anti-CD9 antibody and anti-CD63 antibody (H.U. Group Research Institute, Tokyo)
27 coupled to Dynabeads M-280 Tosylactivated (Thermo Fisher Scientific Inc, Waltham,
28 MA, USA) were added to aliquots (500 μ L) of the serum samples that had been treated
29 with chelate-based PEVIA[®] reagent (H.U. Group Research Institute), followed by
30 incubation on a rotator at 4°C for 18 h. The beads were washed three times with PBS and
31 stored at 4°C until further analysis.
32

33 **Preparation of peptides**

35 EVs were processed using S-Trap micro spin columns (AMR Inc, Tokyo, Japan)
36 according to the manufacturer's instruction with minor modifications. In brief, captured
37 EVs were suspended in 50 μ L of 5% SDS (FUJIFILM Wako Pure Chemical Corporation,
38 Osaka, Japan) in 50mM TEAB buffer (Honeywell Inc, Charlotte, NC, USA), pH7.5. After
39 removing beads, the amount of protein from EVs were determined by Micro BCA™
40 Protein Assay Kit (Thermo Fisher Scientific Inc). 13.8 ng Pierce™ Digestion Indicator
41 for Mass Spectrometry (Thermo Fisher Scientific Inc) was added to lysed samples for
42 quality control of digestion efficiency. The samples were then reduced and alkylated with
43 dithiothreitol (FUJIFILM Wako Pure Chemical Corporation) and iodoacetamide (Nacalai
44 tesque Inc, Kyoto, Japan), respectively. 12% aqueous phosphoric acid (FUJIFILM Wako
45 Pure Chemical Corporation) was added to a final concentration of 1.2% followed by six
46 times the volume of S-Trap protein binding buffer. The sample mixtures were added to
47 S-Trap columns that were prewashed and preconditioned with 0.2 % formic acid in 50 %
48 acetonitrile and S-Trap buffer, respectively. The S-Trap columns were washed with
49 150uL S-Trap buffer. Centrifugation and removal of the flow through were then repeated
50 6 times. Washed columns were incubated with 20uL of digestion buffer containing 0.75ug
51 Trypsin/Lys-C Mix, Mass Spec Grade (Promega Corporation, Madison, WI, USA) for
52 2hr at 47°C. After digestion, peptides were eluted from the S-Trap column, lyophilized
53 with miVac system (Genevac Ltd, Ipswich, United Kingdom), and stored at -80 °C until
54 use.

55

56 **Proteomic analysis with LC-MS**

57 Peptides obtained from EV proteins were reconstituted in 10 μ l of water containing 0.1%
58 formic acid (FA) (Fisher Chemical, Thermo Fisher Scientific Inc). Quantification of
59 peptides was accomplished using Pierce™ Quantitative Fluorometric Peptide Assay
60 (Thermo Fisher Scientific Inc). Proteomic analysis of the peptides was carried out using
61 Q Exactive (Thermo Fisher Scientific Inc.) equipped with UltiMate 3000 Nano LC
62 Systems (Thermo Fisher Scientific Inc.). Peptide samples (1 μ g) were injected onto
63 Acclaim PepMap 1000 trap columns (75 μ m \times 2 cm, nanoViper C18 3 μ m, 100Å, Thermo
64 Fisher Scientific Inc) which were heated to 40 °C in a chamber which was connected to
65 a C18 reverse-phase Aurora UHPLC Emitter Column with nano Zero & Captive Spray
66 Insert (75 μ m \times 25 cm, Ion Opticks Pty Ltd) using Dreamspray interface (AMR Inc). The
67 nano pump flow rate was set to 250 nL/min with a 302 min gradient, in which the mobile
68 phases were A (0.1% FA in water, Fisher Chemical, Thermo Fisher Scientific Inc.) and

69 B (0.1% FA in acetonitrile, Fisher Chemical, Thermo Fisher Scientific Inc.). The
70 chromatography gradient was designed to provide a linear increase from 0-8 min at 2%
71 B, 8-272 min from 2% B to 35% B, 272-282 min from 35% B to 70% B, 282-283 min
72 from 70% B to 95% B, wash, 8 min and 10 min equilibrium. The data-dependent
73 acquisition was performed in positive ion mode. Mass spectrometry parameters and those
74 of the Proteome Discoverer 2.2.0.388 software (Thermo Fisher Scientific Inc) were
75 described in a previous report (doi: <https://doi.org/10.1101/2020.06.17.155861>).

76

77 **Analysis of serum exRNA profiles**

78 Total RNA was extracted from aliquots (200 μ L) of the serum samples using QIAzol and
79 the miRNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's
80 protocol. The library was prepared using the QIAseq miRNA Library Kit (Qiagen).
81 Library preparations were subjected to quality control using either a Bioanalyzer 2100 or
82 TapeStation 4200 system (Agilent Technologies, Santa Clara, CA, USA). The library
83 pools were quantified using the Library Quantification Kit (Takara, Shiga, Japan) and
84 sequenced on the NovaSeq 6000 sequencing platform (Illumina Inc, San Diego, CA,
85 USA). Reads were pre-processed and annotated against miRBase v22.1 and Ensembl
86 non-coding RNA database release 100 by using CLC Genomics Workbench v20.0.1. Raw
87 and normalized microarray data is available in the Gene Expression Omnibus database
88 (GSE158877).

89

90 **Statistical analysis**

91 Fisher's exact test for categorical variables and unpaired Student's *t*-test for continuous
92 variables were used to compare clinical data between two groups. To identify biomarker
93 candidates among EV proteins and exRNAs, we initially used one-way analysis of
94 variance (ANOVA) to select candidates present at different levels in the three subject
95 groups (uninfected, COVID-19 Group 1, and Group 2) with $P < 0.05$. Principal
96 component analysis (PCA) was performed with the selected candidates using Partek
97 Genomics Suite 7.0 (Partek, St. Louis, MO, USA). Second, candidates with better
98 discrimination between Group 1 and 2 were selected based on linear discriminant analysis
99 with leave-one-out cross-validation, and subsequent ROC analysis was performed using
100 R version 3.6.3 (R Foundation for Statistical Computing, <http://www.R-project.org>),
101 compute.es package version 0.2-2, hash package version 2.2.6.1, MASS package version
102 7.3-51.5, mutoss package version 0.1-12, and pROC package version 1.16.2. Optimal cut-

103 off values for each candidate were set based on the maximum point of the sum of
104 sensitivity and specificity (Youden index). Predictive sensitivity, specificity, and
105 accuracy were calculated with the corresponding cut-off value for each candidate.
106 Kaplan–Meier analysis with log-rank test and Cox regression analysis were performed
107 using IBM SPSS Statistics 25 (IBM Japan, Tokyo, Japan). The correlation plot was
108 generated using R version 3.6.3 and corrplot package version 0.84., and the unsupervised
109 hierarchical clustering analysis was performed using Partek Genomics Suite 7.0. The
110 limit of statistical significance for all analyses was defined as a two-sided P value of 0.05.
111
112

113 **Supplementary Data**

114 **Figure S1.** Clinical factors at admission for early prediction of COVID-19 severity.

115

116 **Table S1.** Baseline characteristics of healthy donors and COVID-19 patients.

117 **Table S2.** WHO 2020 scoring for COVID-19 cases used in this study.

118 **Table S3.** Differences in clinical characteristics among healthy donors and COVID-19
119 patients.

120 **Table S4.** EV proteins for discrimination between mild and severe COVID-19 patients.

121 **Table S5.** ExRNAs for discrimination between mild and severe COVID-19 patients.

122 **Table S6.** Univariate Cox regression analysis of the selected factors and biomarkers for
123 predicting COVID-19 severity in this patient cohort.

124




Figure S1. Clinical factors at admission for early prediction of COVID-19 severity. (a) Patient recruitment flowchart for this cohort. (b) Correlations of age, smoking index, CRP, and ALT between the three subject groups. P values for trend by *Pearson's* correlation analysis. Error bars represent mean \pm SEM. (c) The AUC (95% CI) for age, smoking index, CRP, and ALT evaluated by ROC analysis. (d) Kaplan-Meier curves for age, smoking index, CRP, and ALT by Log-rank test. Time represents the number of days from admission to time of onset for a severe COVID-19 related event. In each case, optimal cut-off values were used to define high and low groups.

Table S1. Baseline characteristics of healthy donors and COVID-19 patients.

	Patients	WHO score	WHO category	Age (10-year range)	Sex	Onset of severe events (day) [†]	The period of hospital stay	Outcome
Healthy donor	HD-1	0	uninfected	30's	M	-	-	-
	HD-2	0	uninfected	30's	M	-	-	-
	HD-3	0	uninfected	20's	F	-	-	-
	HD-4	0	uninfected	40's	M	-	-	-
	HD-5	0	uninfected	70's	M	-	-	-
	HD-6	0	uninfected	50's	M	-	-	-
	HD-7	0	uninfected	60's	M	-	-	-
	HD-8	0	uninfected	40's	M	-	-	-
	HD-9	0	uninfected	50's	M	-	-	-
	HD-10	0	uninfected	30's	F	-	-	-
Group 1 COVID-19	1	3→3	mild→mild	30's	M	-	15	discharged
	2	3→3	mild→mild	30's	M	-	14	discharged
	3	3→3	mild→mild	40's	M	-	10	discharged
	4	3→3	mild→mild	40's	M	-	13	discharged
	5	3→3	mild→mild	50's	M	-	21	discharged
	6	3→3	mild→mild	50's	M	-	26	discharged
	7	3→3	mild→mild	80's	M	-	28	discharged
	8	3→3	mild→mild	50's	F	-	25	discharged
	9	3→3	mild→mild	20's	F	-	11	discharged
	10	3→3	mild→mild	20's	F	-	23	discharged
	11	3→3	mild→mild	40's	F	-	15	discharged
	12	3→3	mild→mild	40's	M	-	12	discharged
	13	3→3	mild→mild	70's	M	-	47	discharged
	14	3→3	mild→mild	40's	M	-	54	discharged
	15	3→3	mild→mild	40's	M	-	9	discharged
	16	3→3	mild→mild	50's	M	-	15	discharged
	17	3→3	mild→mild	30's	F	-	12	discharged
	18	3→3	mild→mild	50's	M	-	18	discharged
	19	3→3	mild→mild	40's	F	-	21	discharged
	20	3→3	mild→mild	30's	M	-	0	to medical facility
	21	3→3	mild→mild	30's	F	-	0	to medical facility
	22	3→3	mild→mild	40's	M	-	7	discharged
Group 2 COVID-19	23	3→7	mild→severe	60's	M	5	93	discharged
	24	3→7	mild→severe	80's	M	4	23	death (pulmonary embolism)
	25	3→7	mild→severe	60's	M	3	138	still hospitalized
	26	3→7	mild→severe	70's	M	9	44	discharged
	27	3→7	mild→severe	70's	M	7	29	discharged
	28	3→7	mild→severe	70's	M	7	125	still hospitalized
	29	3→7	mild→severe	50's	M	10	43	death (ARDS)
	30	3→6	mild→severe	50's	M	5	31	discharged
	31	3→5	mild→severe	50's	M	7	16	discharged

M, male; F, female; † Day after sampling point on admission.

Table S2. WHO 2020 scoring for COVID-19 cases used in this study.

Patient	Descriptor	Score
Uninfected	No clinical or virological evidence of infection	0
Ambulatory	No limitation of activities	1
	Limitation of activities	2
Hospitalized-mild disease	No oxygen therapy	3
	Oxygen by nasal prongs or mask	4
Hospitalized-severe disease	Non-invasive ventilation of high-flow oxygen	5
	Intubation and mechanical ventilation	6
	Ventilation + additional organ support (pressors, RRT, ECMO)	7

RRT, renal replacement therapy; ECMO, extracorporeal membrane oxygenation.

Table S3. Differences in clinical characteristics among healthy donors and COVID-19 patients.

	uninfected (n=10)	Group 1 COVID-19 (n=22)	Group 2 COVID-19 (n=9)	P value	
				(uninfected vs. infected)	(Group 1 vs. Group 2)
Age (year)	46.5 ± 14.8	45.3 ± 14.3	65.4 ± 9.5	0.42	0.001
Sex					
Men	8 (80%)	15 (68.2%)	9 (100%)	1.00	0.08
Women	2 (20%)	7 (31.8%)	0 (0%)		
BMI (kg/m ²)	22.8 ± 4.4	23.0 ± 3.0 (n=20)	22.4 ± 3.2	0.95	0.63
Smoking index	176 ± 237	60 ± 140	427 ± 670	0.94	0.02
WBC count (10 ³ /μL)	6.7 ± 2.9	4.6 ± 1.5	5.2 ± 3.2	0.03	0.46
CRP (mg/dL)	0.12 ± 0.12	2.50 ± 2.41	6.07 ± 5.11	0.01	0.01
BUN (mg/dL)	13.7 ± 4.5	17.0 ± 16.6	22.6 ± 14.6	0.35	0.39
Cr (mg/dL)	0.84 ± 0.13	1.72 ± 3.22	1.88 ± 2.4	0.33	0.90
ALT (IU/L)	22.5 ± 8.5	21.4 ± 15.2	42.6 ± 33.2	0.51	0.02
CK (IU/L)	NA	69.5 ± 44.1	71.8 ± 50.8	NA	0.90
D-dimer (μg/mL)	NA	1.8 ± 2.0 (n=12)	1.1 ± 0.4	NA	0.28
Fbg (mg/dL)	NA	389.0 ± 84.2 (n=7)	480.4 ± 172.2	NA	0.22
Hypertension	2 (20.0%)	6 (27.3%)	3 (33.3%)	0.70	1.00
Diabetes mellitus	0 (0%)	5 (22.7%)	3 (33.3%)	0.17	0.66
Dyslipidemia	0 (0%)	4 (18.2%)	3 (33.3%)	0.16	0.38
Colony heart disease	0 (0%)	2 (9.1%)	0 (0%)	1.00	1.00

Continuous variables were expressed as mean ± SD and tested by unpaired Student's *t*-test. Categorical variables were expressed as n (%) and tested by Fisher's exact test.

Table S4. EV proteins for discrimination between mild and severe COVID-19 patients.

GeneName	Cross-validation score	Sensitivity	Specificity	Accuracy	AUC
COPB2	1.00	1.00	1.00	1.00	1.00
KRAS	0.90	1.00	0.82	0.87	0.93
PRKCB	0.90	0.89	0.95	0.94	0.93
RHOC	0.90	0.78	1.00	0.94	0.96
CD147	0.87	0.67	0.91	0.84	0.73
CAPN2	0.87	0.89	0.77	0.81	0.84
ECM1	0.87	0.67	0.95	0.87	0.82
FGG	0.87	0.67	1.00	0.90	0.87
MFAP4	0.87	0.56	1.00	0.87	0.75
ADI1	0.84	0.67	0.95	0.87	0.88
AK1	0.84	0.89	0.91	0.90	0.95
MGAT1	0.84	1.00	0.77	0.84	0.91
CLDN3	0.84	0.89	0.82	0.84	0.86
CRP	0.84	0.78	0.77	0.77	0.82
UQCRC2	0.84	0.78	0.82	0.81	0.77
FGA	0.84	0.67	0.95	0.87	0.88
FGB	0.84	0.67	1.00	0.90	0.84
FGL1	0.84	0.78	0.82	0.81	0.85
GPX1	0.84	0.67	0.91	0.84	0.81
GSK3B	0.84	0.44	1.00	0.84	0.73
LBP	0.84	0.78	0.86	0.84	0.82
PDGFC	0.84	0.89	0.77	0.81	0.86
RAB13	0.84	0.78	0.86	0.84	0.85
RAP1B	0.84	0.67	1.00	0.90	0.91
SLC6A4	0.84	0.89	0.82	0.84	0.90
UBA7	0.84	0.78	0.86	0.84	0.83
ORM1	0.81	0.89	0.59	0.68	0.80
RNPEP	0.81	0.56	0.95	0.84	0.68
ANGPT1	0.81	0.78	0.86	0.84	0.88
APOB	0.81	0.78	0.86	0.84	0.79
B4GALT1	0.81	0.67	0.95	0.87	0.79
BHMT	0.81	0.44	1.00	0.84	0.74
CPN1	0.81	0.89	0.68	0.74	0.84
GNAZ	0.81	1.00	0.95	0.97	0.99
ICAM2	0.81	1.00	0.59	0.71	0.83
SELL	0.81	0.67	0.91	0.84	0.74
MAN1A1	0.81	0.78	0.82	0.81	0.85
SERPINA5	0.81	0.89	0.82	0.84	0.81
PACSIN2	0.81	0.89	0.86	0.87	0.90
NCF1B	0.81	0.89	0.55	0.65	0.73
TMEM59	0.81	0.44	0.95	0.81	0.59
YWHAB	0.77	0.67	0.95	0.87	0.85
ABAT	0.77	0.33	1.00	0.81	0.52
ADH1B	0.77	0.67	0.95	0.87	0.79
ASL	0.77	0.67	0.91	0.84	0.80
ASS1	0.77	0.78	0.86	0.84	0.79
CDH2	0.77	0.56	0.95	0.84	0.69
CAB39	0.77	0.89	0.91	0.90	0.94
CPS1	0.77	0.67	0.82	0.77	0.74
CD226	0.77	0.67	1.00	0.90	0.87
COL6A3	0.77	0.67	0.86	0.81	0.82
CUL4A	0.77	0.78	0.64	0.68	0.75
DSC1	0.77	0.44	0.95	0.81	0.58
ENTPD5	0.77	1.00	0.64	0.74	0.86
EIF4A1	0.77	0.67	0.86	0.81	0.80
FN1	0.77	0.89	0.68	0.74	0.81
PGC	0.77	0.89	0.68	0.74	0.78
RHEB	0.77	1.00	0.59	0.71	0.84
GNAI2	0.77	0.89	0.59	0.68	0.79
GNB1	0.77	0.78	0.77	0.77	0.83
GNA13	0.77	0.67	0.95	0.87	0.86
ITGA2B	0.77	0.67	0.91	0.84	0.86
ITGB1	0.77	1.00	0.59	0.71	0.84
ILK	0.77	0.89	0.77	0.81	0.84
F11R	0.77	1.00	0.50	0.65	0.82
LTA4H	0.77	0.56	0.91	0.81	0.67
LIMS1	0.77	0.89	0.77	0.81	0.83
NAV2	0.77	0.56	0.86	0.77	0.73
FAM129B	0.77	0.78	0.86	0.84	0.84
NNMT	0.77	0.67	0.91	0.84	0.69
NID1	0.77	0.89	0.55	0.65	0.76
PPIA	0.77	0.78	0.77	0.77	0.86
PLA1A	0.77	0.67	0.91	0.84	0.80
PPBP	0.77	0.67	0.77	0.74	0.69
PECAM1	0.77	1.00	0.55	0.68	0.82
GP1BB	0.77	0.67	0.86	0.81	0.81
PCSK9	0.77	1.00	0.82	0.87	0.91
MENT	0.77	0.44	0.95	0.81	0.71
SERPINA10	0.77	0.67	0.82	0.77	0.74
F2RL3	0.77	0.89	0.86	0.87	0.91
LOX	0.77	0.67	0.91	0.84	0.81
SFTPB	0.77	0.67	0.77	0.74	0.78
RAB5B	0.77	0.78	0.86	0.84	0.84
RALB	0.77	0.89	0.68	0.74	0.82
REEP6	0.77	0.78	0.68	0.71	0.71
RETN	0.77	0.67	0.73	0.71	0.69
AGXT	0.77	0.22	1.00	0.77	0.48
CCT2	0.77	0.89	0.64	0.71	0.81
THBD	0.77	0.56	0.91	0.81	0.74
ISG15	0.77	0.33	1.00	0.81	0.67
ZYX	0.77	1.00	0.55	0.68	0.82

Table S5. ExRNAs for discrimination between mild and severe COVID-19 patients.

Transcript	Cross-validation score	Sensitivity	Specificity	Accuracy	AUC
miR-122-5p	0.84	0.56	1.00	0.87	0.81
SNORD33	0.84	1.00	0.73	0.81	0.89
AL732437.2	0.84	0.89	0.68	0.74	0.80
RNU2-29P	0.81	0.44	1.00	0.84	0.70
CDKN2B-AS1	0.81	0.67	0.95	0.87	0.86
AL365184.1	0.81	0.78	0.86	0.84	0.87
AL365184.1	0.81	0.78	0.91	0.87	0.90
AL365184.1	0.81	0.67	0.91	0.84	0.87
AL365184.1	0.81	0.78	0.91	0.87	0.90
AL365184.1	0.81	1.00	0.73	0.81	0.92
let-7c-5p	0.77	0.44	0.95	0.81	0.75
miR-21-5p	0.77	0.56	0.91	0.81	0.71
miR-140-3p	0.77	0.89	0.77	0.81	0.89
C5orf66-AS2	0.77	0.78	0.91	0.87	0.89

Table S6. Univariate Cox regression analysis of the selected factors and biomarkers for predicting COVID-19 severity in this patient cohort.

	Cut-off	HR	(95% CI)	P value
Age high	56.5	28.1	(3.4 - 231.9)	0.0019
Smoking index high	87.5	3.1	(0.8 - 11.6)	0.092
CRP high	2.3	8.4	(1 - 67.5)	0.045
ALT high	21.5	3.8	(0.8 - 18.5)	0.095
COPB2 low	1.6 x10 ⁸	NA	-	-
KRAS low	4.8 x10 ⁷	189.8	(0.4 - 9.0 x10 ⁴)	0.095
PRKCB low	6.3 x10 ⁷	32.1	(3.9 - 261.9)	0.0012
RHOC low	1.4 x10 ⁷	23.6	(4.7 - 118)	0.00012
CD147 high	6.1 x10 ⁸	10.7	(2.5 - 45.1)	0.0013
CAPN2 high	7.2 x10 ⁵	15.5	(1.9 - 125.9)	0.010
ECM1 high	2.3 x10 ⁸	11.6	(2.8 - 48.4)	0.00079
FGG high	1.4 x10 ¹⁰	21.4	(4.2 - 110.4)	0.00025
MFAP4 high	4.6 x10 ⁸	12.7	(3.3 - 48.6)	0.00022
miR-122-5p high	1.0 x10 ⁵	10.5	(2.7 - 40.4)	0.00063
SNORD33 high	406.6	104.1	(0.4 - 2.7 x10 ⁴)	0.10
AL732437.2 high	8.8	9.9	(1.2 - 79.9)	0.031
RNU2-29P high	124.1	10.4	(2.6 - 40.8)	0.00081
CDKN2B-AS1 high	6.2	14.4	(3.4 - 61.3)	0.00031
AL365184.1 high	2.9	14.2	(1.8 - 114.4)	0.013

HR, hazard ratio; CI, confidence interval; NA, not applicable